
Identification of biomarkers predictive of sensitivity to the CHK1/2 inhibitor ACR-368 using high-resolution phosphoproteomics and development of an ACR-368-tailored patient responder identification 3-marker test, ACR-368 OncoSignature

Caroline Wigerup¹, Michail Shipitsin², Ayesha Murshid², Lei Shi², Joon Jung², Javid Proia², Jesper V. Olsen³, Kristina Masson², Peter Blume-Jensen² ¹Acrivon AB, Medicon Village, Lund, Sweden, ²Acrivon Therapeutics Inc., Watertown, MA, USA, ³CPR, University of Copenhagen, Denmark



tive biomarkers abrogates sensitivity to ACR-368 in OVCAR3 cells. (C) Example of nuclear biomarker levels in sensitive and resistant cell lines.

